See more : UEM Sunrise Berhad (5148.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Canntab Therapeutics Limited (CTABF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Canntab Therapeutics Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Acast AB (publ) (ACAST.ST) Income Statement Analysis – Financial Results
- Pasinex Resources Limited (PSE.CN) Income Statement Analysis – Financial Results
- Crossword Cybersecurity Plc (CCS.L) Income Statement Analysis – Financial Results
- SkyCity Entertainment Group Limited (SKC.NZ) Income Statement Analysis – Financial Results
- Linzhou Heavy Machinery Group Co.,Ltd (002535.SZ) Income Statement Analysis – Financial Results
Canntab Therapeutics Limited (CTABF)
About Canntab Therapeutics Limited
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 293.36K | 0.00 | 133.33K | 240.00K | 26.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.16K | 0.00 |
| Cost of Revenue | 1.23M | 546.34K | 0.00 | 96.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -939.01K | -546.34K | 133.33K | 143.61K | 26.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.16K | 0.00 |
| Gross Profit Ratio | -320.09% | 0.00% | 100.00% | 59.84% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 205.03K | 80.36K | 105.75K | 128.14K | 140.73K | 40.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.60M | 2.58M | 2.34M | 2.44M | 2.13M | 1.07M | 173.84K | 178.77K | 312.39K | 346.86K | 366.02K | 49.91K |
| Selling & Marketing | 226.39K | 128.18K | 168.51K | 0.00 | 126.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.83M | 2.70M | 2.34M | 2.44M | 2.26M | 1.07M | 173.84K | 178.77K | 312.39K | 346.86K | 366.02K | 49.91K |
| Other Expenses | 192.91K | -429.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.23M | 3.33M | 2.75M | 2.74M | 2.45M | 1.12M | 173.84K | 178.77K | 587.32K | 1.45M | 1.46M | 100.41K |
| Cost & Expenses | 4.46M | 3.33M | 2.75M | 2.74M | 2.45M | 1.12M | 173.84K | 178.77K | 587.32K | 1.45M | 1.46M | 100.41K |
| Interest Income | 0.00 | 0.00 | 8.46K | 43.19K | 15.01K | 313.00 | 0.00 | 0.00 | 429.00 | 4.51K | 10.16K | 0.00 |
| Interest Expense | 566.67K | 188.72K | 26.58K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 634.72K | 546.34K | 295.62K | 80.61K | 51.48K | 1.62K | -347.68K | -236.00 | -235.27K | 223.75K | 0.00 | 0.00 |
| EBITDA | -2.49M | -3.13M | -2.32M | -2.42M | -2.37M | -1.11M | -173.84K | -179.00K | -872.97K | -1.33M | -1.45M | -100.41K |
| EBITDA Ratio | -848.03% | 0.00% | -1,740.06% | -1,008.82% | -8,894.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,293.36% | 0.00% |
| Operating Income | -4.16M | -3.78M | -2.62M | -2.50M | -2.42M | -1.12M | 173.84K | -178.77K | -637.71K | -1.56M | -1.45M | -100.41K |
| Operating Income Ratio | -1,419.41% | 0.00% | -1,961.77% | -1,042.41% | -9,087.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,293.36% | 0.00% |
| Total Other Income/Expenses | 474.83K | -900.30K | 0.00 | 43.19K | 15.01K | 313.00 | -347.68K | 236.00 | 336.46K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -3.69M | -4.42M | -2.61M | -2.46M | -2.41M | -1.12M | -173.84K | -178.53K | -301.24K | -1.56M | 0.00 | 0.00 |
| Income Before Tax Ratio | -1,257.55% | 0.00% | -1,955.42% | -1,024.41% | -9,031.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 188.72K | 89.32K | -91.25K | 0.00 | -50.90K | -370.50K | 0.00 | -50.81K | -114.13K | 1.45M | 100.41K |
| Net Income | -3.69M | -4.42M | -2.61M | -2.46M | -2.41M | -1.12M | -173.84K | -178.53K | -301.24K | -1.56M | -1.45M | -100.41K |
| Net Income Ratio | -1,257.55% | 0.00% | -1,955.42% | -1,024.41% | -9,031.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,293.36% | 0.00% |
| EPS | -0.10 | -0.13 | -0.10 | -0.10 | -0.11 | -0.07 | -0.75 | -1.18 | -1.53 | -8.30 | -9.38 | -1.65 |
| EPS Diluted | -0.10 | -0.13 | -0.10 | -0.10 | -0.11 | -0.07 | -0.75 | -1.18 | -1.53 | -8.30 | -9.38 | -1.65 |
| Weighted Avg Shares Out | 37.72M | 34.55M | 27.17M | 25.30M | 21.13M | 15.00M | 230.28K | 151.38K | 196.69K | 187.58K | 154.73K | 60.70K |
| Weighted Avg Shares Out (Dil) | 37.72M | 34.55M | 27.17M | 25.30M | 21.13M | 15.00M | 230.28K | 151.38K | 196.69K | 187.58K | 154.73K | 60.70K |
CSE Bulletin: Delist - Canntab Therapeutics Limited (PILL)
Toronto, Ontario--(Newsfile Corp. - le 14 juin/June 2024) - The common shares of Canntab Therapeutics Limited will be delisted from the CSE at market close today, June 14, 2024. Canntab Therapeutics is currently suspended.
Canntab Therapeutics Limited Provides Update on Application for Management Cease Trade Order
Toronto, Ontario--(Newsfile Corp. - September 18, 2023) - Canntab Therapeutics Limited (CSE: PILL) (OTC Pink: CTABF) (FSE: TBF1) (the "Corporation") announces that the Ontario Securities Commission (the "OSC") has rejected the Corporation's application for a management cease trade order (the...
Canntab Therapeutics seeks to move manufacturing process as Markham lease expires
Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) has provided an update on several matters impacting the company, including plans to move its manufacturing operations following expiry of its lease at the Markham facility. The company, which is a leading innovator in cannabinoid...
Canntab Therapeutics provides update on recent product delivery of its cannabinoid solutions to the Nova Scotia Liquor Corporation
Canntab Therapeutics Limited has provided an update on the recent product delivery of its unique pharmaceutical cannabinoid solutions to the Nova Scotia Liquor Corporation (NSLC). The company said that on August 15, 2022, it completed its first shipment of 5mg...
Canntab Therapeutics appoints Hamish Sutherland as strategic business consultant
Canntab Therapeutics Ltd said it has appointed Hamish Sutherland as a strategic business consultant to develop additional sales and distribution channels for the company's products and to assist it in reaching strategic partnerships in the cannabis industry. A seasoned veteran of...
Canntab Therapeutics inks affiliate deal with independent pharmacy owners in Ontario
Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) announced that it has entered into an affiliate agreement with OnPharm-United, a 600-plus network of independent pharmacy owners throughout the Province of Ontario. The company said all member pharmacies will have access to educational information on medical cannabis,...
Canntab Therapeutics closes non-brokered private placement of secured convertible debentures for gross proceeds of $1,312,000
Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) said it has closed a non-brokered private placement of secured convertible debentures of the company, under which the company issued and will issue debentures for gross proceeds of $1,312,000. The proceeds will be used to...
Levitee Labs Teams Up With Canntab Therapeutics, Offer Cannabinoid Products As Alternatives To Opioids
Wellness company Levitee Labs Inc. (CSE:LVT) (OTC:LVTTF) (FSE:7H7) confirmed Monday that it has teamed up with cannabinoid company Canntab Therapeutics Limited (CSE:PILL) (OTCQB:CTABF) (FRA: TBF1.F). Canntab is known for developing cannabinoid and terpene blends in hard pill form for therapeutic applications...
Canntab Therapeutics Completes First Shipment Of THC Tablets To Ontario Cannabis Stores
Canntab Therapeutics Limited (CSE:PILL) (OTCQB:CTABF) (FRA: TBF1.F), an innovator in cannabinoid and terpene blends, said Monday that it has completed its first shipment of 5 mg THC tablets to the Ontario Cannabis Store. The Toronto-based company finalized the shipment on...
Levitee Labs partners with Canntab Therapeutics to provide alternative to drugs amid opioid crisis in Canada
Levitee Labs (CSE:LVT) Inc said it has entered into a strategic partnership via a service agreement with Canntab Therapeutics Limited to contribute towards correcting the opioid crisis in Canada. Under this partnership, Levitee will inform customers throughout its ecosystem of...
Source: https://incomestatements.info
Category: Stock Reports